LGD-4033

Volume: 30 ML

Dosage: 10/25 MG/ML

Clinical dosing: 5 -20 mg/day

Description:

LGD-4033 (often also called as Ligandrol) is a oral, nonsteroidal and potent selective androgen receptor modulator (SARM). It was developed to increase anabolic activity and reduce muscle wasting in people with severe diseases associated with catabolic conditions and critical loss of muscle mass. In clinical trials, LGD-4033 has shown significant anabolic activity in muscles and antiresorptive and anabolic activity in bones, along with a high selectivity to act in these tissues (where appropriate and desirable) and minimally in other tissues and organs, where undesirable. LGD-4033 binds to androgen receptor with high affinity (Ki of ∼1 nM) and selectivity, has chemical formula C14H12F6N2O, molecular mass 338.253 g·mol−1, prolonged elimination half-life 24–36 hours and linear pharmacokinetics. SARM LGD-4033 (Ligandrol) was discovered by Ligand Pharmaceuticals and is currently being developed (under the new designation VK5211) by Viking Therapeutics, which currently does not manufacture any pharmaceutical products but develops several products for the treatment of metabolic and endocrine disorders. Viking Therapeutics assumed the largest expense in 2014 from cited Research and Development costs ($21.2M), which may be related to purchase of required equipment and facilities to develop the drug candidates licensed by Ligand Pharmaceuticals in that year, including LGD-4033. Another promising drug candidate, VK2809, is expected to drive a major shift in the market cap of Viking Therapeutics and its share of the market for TRβ agonists. In the United States, LGD-4033 is currently an investigational compound. SARM LGD-4033 is a nonsteroidal selective androgen receptor modulator that is expected to deliver the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanisms of action and oral routes of administration. The research carried out indicates that LGD-4033 seems to be promising candidate for treatment of serious diseases associated with muscle wasting in future, however, the long-term effects of LGD-4033 are not fully known and investigated so far, and further research is still needed.

certification:

Compound Specifications:

Originale product made in UK.